Navigation Links
Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
Date:5/7/2008

n is characterized by persistent sadness and loss of interest in usual activities. While the brain chemistry of depression is not fully understood, research suggests that depression is caused by an imbalance of certain chemicals in the brain, most notably serotonin.

Despite advances and progress in identifying and treating mental disorders in adolescents, depression in this population remains under-treated. Depression is a chronic disease that requires medical attention and treatment, and if left untreated, may have serious consequences. According to the National Alliance on Mental Illness (NAMI), adolescents with untreated depression are likely to have ongoing problems in school, at home and with their friends.

For adolescents who suffer from depression, psychotherapy, cognitive-behavior therapy, interpersonal therapy and medication play an important role in the management of their illness. Patients on antidepressant treatment should also be closely monitored by healthcare providers, family members and other caregivers.

About Lexapro

Lexapro is an SSRI being studied as a treatment for adolescents with MDD. Lexapro is indicated for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder (GAD) in adults. Lexapro is thought to work by helping to restore the brain's chemical balance. It is believed to increase the availability of serotonin, a substance in the brain believed to influence mood. In adults, Lexapro 10 mg/day is a well-tolerated therapy, with drop-out rates due to adverse events comparable to placebo treatment in depression trials. Lexapro has been prescribed to over 16 million people.

Important Lexapro Information

Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Antidepressants increased the risk of suicidality (suicidal thinking and behavior) in children, adolescents, and young adults in short-term studie
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
2. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
3. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
4. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
5. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
6. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
7. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
8. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... BRISBANE, Calif., Oct. 27, 2011 InterMune, Inc. (NASDAQ: ... third quarter 2011 financial results at the close of the ... call and webcast will be hosted by InterMune at 4:30 ... and others may participate in the conference call by dialing ...
... 2011 Total quarterly revenues of ... grow 17 Percent, reflecting strong performance of OPANA® ER, Voltaren® Gel ... of $0.34 versus $0.46 for prior year ... from 2010 Company reaffirms 2011 guidance ...
Cached Medicine Technology:InterMune to Release Third Quarter Financial Results on November 3 2Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 2Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 3Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 4Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 5Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 6Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 7Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 8Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 9Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 10Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 11Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 12Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 13Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 14Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 15Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 16Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 17
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
(Date:4/17/2014)... online has the potential to ward off depression among ... research published online in The Journals of ... . In the article " Internet Use and Depression ... Longitudinal Analysis ," the authors report that Internet use ... percent among their study sample. , Late-life depression ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2
... , ... brings seamless source control management (SCM) to applications and databases. Rational Team Concert customers ... changes resulting in entire projects being deployed in a process-controlled, audited and compliant fashion. ... ...
... ... college, by entering the B’nai B’rith International Diverse Minds Youth Writing Challenge. The teens ... diversity. The winners take home $5,000 college scholarships and will see their books professionally ... (PRWEB) ...
... ... the summer of 2008. At that time, the thought of using cellular technology ... terms of the paper processes that were in place at the time. Now ... and the thought of going back to paper does not even exist. ...
... an editorial about the Reduction by Dutasteride of Prostate Cancer ... Roobol was published in the online version of European ... Urology (EAU). The long-expected final report of the ... New England Journal of Medicine [1] together with a ...
... Do some currently available lubricants used for anal sex ... , The answer is: we don,t know. , ... Microbicide Advocates), brand new research from the Microbicide Trials ... this critical question. , Today at the 2010 ...
... reputable and frequently updated websites and not see online research ... paper in the May issue of the Journal of ... a team from the University of Florida, USA, found that ... get answers to health-related questions, but only 28 to 41 ...
Cached Medicine News:Health News:dbMaestro Achieves “Ready For IBM Rational Software” Validation For Rational Team Concert Integration 2Health News:High School Students Well-Schooled In Diversity: Teen Winners of Book Writing Contest Earn College Scholarships and Have Entries Published 2Health News:Caldwell Hospice Upgrades to Latest Version of CellTrak 2Health News:European Urology: Editorial about REDUCE trial underlines value of dutasteride 2Health News:GATOR approach can help surfers to evaluate Web-based health information 2Health News:GATOR approach can help surfers to evaluate Web-based health information 3
ROB-NEL Catheters (100% Latex-Free)...
Urethral Red Rubber Catheters (Latex)...
ULTRAMER Foley Catheter...
Silicone-Coated Foley Catheter 2-Way...
Medicine Products: